Status:
COMPLETED
SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will evaluate the efficacy and safety of 4 regimens of PEGASYS plus Copegus, in patients with chronic hepatitis C (CHC) genotype 1 who have failed to respond to previous treatment with stan...
Eligibility Criteria
Inclusion
- adult patients \>=18 years of age, with CHC genotype 1;
- patients who have failed to respond to previous treatment with PEGASYS plus ribavirin for \>=12 weeks;
- patients who have discontinued PEGASYS/ribavirin \>=4 weeks prior to enrollment;
- compensated liver disease.
Exclusion
- other forms of liver disease;
- infection with HIV, HAV, HBV;
- hepatocellular cancer.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT00412334
Start Date
January 1 2007
End Date
September 1 2010
Last Update
April 5 2016
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Angers, France, 49033
2
Bobigny, France, 93009
3
Châteauroux, France, 36019
4
Créteil, France, 94000